Drug Profile
Research programme: anti-inflammatory therapeutics - Protectimmun
Latest Information Update: 18 Sep 2023
Price :
$50
*
At a glance
- Originator Protectimmun
- Class Anti-inflammatories; Polysaccharides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Autoimmune disorders
Most Recent Events
- 18 Sep 2023 Discontinued - Preclinical for Autoimmune disorders in Germany (unspecified route) (Protectimmun pipeline, September 2023)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Autoimmune-disorders in Germany
- 05 Aug 2016 Preclinical trials in Autoimmune disorders in Germany (unspecified route)